Skyrizi Kesatuan Eropah - Hungary - EMA (European Medicines Agency)

skyrizi

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunszuppresszánsok - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Verquvo Kesatuan Eropah - Hungary - EMA (European Medicines Agency)

verquvo

bayer ag - vericiguat - szív elégtelenség - cardiac terápia - treatment of symptomatic chronic heart failure.

Adtralza Kesatuan Eropah - Hungary - EMA (European Medicines Agency)

adtralza

leo pharma a/s - tralokinumab - dermatitis, atopic - egyéb bőrgyógyászati ​​készítmények - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Amvuttra Kesatuan Eropah - Hungary - EMA (European Medicines Agency)

amvuttra

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - egyéb idegrendszeri gyógyszerek - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Spevigo Kesatuan Eropah - Hungary - EMA (European Medicines Agency)

spevigo

boehringer ingelheim international gmbh - spesolimab - pikkelysömör - immunszuppresszánsok - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Omvoh Kesatuan Eropah - Hungary - EMA (European Medicines Agency)

omvoh

eli lilly nederland b.v. - mirikizumab - colitis, ulceratív - immunszuppresszánsok - omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.